PD-1/PD-L1 inhibitors plus anti-angiogenic TKIs improve PFS but not OS in advanced NSCLC
Does combining these lung cancer drugs extend life, or just delay disease growth?
A meta-analysis of 2,787 patients with advanced or metastatic NSCLC found that combining PD-1/PD-L1 inhibitors with multi-targeted anti-angi…
Combining lung cancer drugs slows disease growth but offers no clear survival benefit for patients with advanced non-small cell lung cancer.
SBRT shows early QoL advantage over CHRT in inoperable stage I NSCLC, but long-term scores converge
Which radiation therapy helps people with inoperable lung cancer feel better?
A phase 3 RCT of 233 patients with medically inoperable stage I NSCLC compared SBRT to CHRT.
For inoperable lung cancer, a newer radiation method offers early relief but conventional therapy catches up in overall health by two years.
Benmelstobart plus anlotinib improves progression-free survival versus pembrolizumab plus placebo in first-line PD-L1-positive advanced NSCLC
New drug combo may extend time before cancer grows in lung patients
This randomised, controlled, phase 3 trial evaluated benmelstobart plus anlotinib versus pembrolizumab plus placebo in patients with PD-L1-p…
A new drug combo may extend the time before cancer grows in lung patients who have not yet received treatment for their advanced disease.
BACE plus tislelizumab shows activity in advanced NSCLC patients ineligible for standard care
Combination treatment shows promise for advanced lung cancer patients ineligible for standard care
A Phase II, single-arm trial in 30 patients with Stage IIIA-IIIC NSCLC who refused or were ineligible for standard treatment evaluated bronc…
A new combo treatment for advanced lung cancer patients ineligible for standard care helped 60% shrink tumors and extended survival to 15 mo…
Firmonertinib plus anlotinib shows preliminary efficacy in advanced EGFR-mutant NSCLC
Early trial shows firmonertinib plus anlotinib helps some advanced lung cancer patients
This single-arm, phase I/II trial evaluated firmonertinib combined with anlotinib in patients with advanced non-small cell lung cancer (NSCL…
Combining firmonertinib and anlotinib helped 64% of advanced lung cancer patients shrink tumors and keep disease controlled for over a year …
Nivolumab with chemotherapy and bevacizumab shows improved 4-year survival in advanced nonsquamous NSCLC
Nivolumab combination shows long-term survival benefit in advanced lung cancer trial
A Phase III randomized controlled trial of 550 patients with advanced nonsquamous NSCLC found nivolumab with carboplatin, paclitaxel, and be…
Adding nivolumab to standard lung cancer treatment helped patients live longer, with 34.7% surviving four years compared to 22.1% on placebo…
Rezivertinib improves CNS progression-free survival versus gefitinib in EGFR-mutated NSCLC with baseline CNS metastases
Rezivertinib shows longer brain metastasis control than gefitinib in lung cancer trial
A phase III randomized controlled trial in 159 treatment-naïve patients with EGFR-mutated NSCLC and baseline CNS metastases found rezivertin…
Rezivertinib kept brain cancer growth in lung cancer patients under control for nearly two years longer than gefitinib in a major trial.
Fulzerasib plus cetuximab shows 69% response in first-line KRAS-mutated NSCLC
Can a new drug combination shrink lung tumors in people with a specific KRAS mutation?
A single-arm phase 1b/2 trial in 47 treatment-naive patients with KRAS-mutated NSCLC found a confirmed objective response rate of 69% (90% C…
A new two-drug combination shrank tumors in nearly 70% of people with advanced lung cancer driven by a specific genetic mutation.
Perioperative tislelizumab plus chemotherapy improves survival in Chinese patients with resectable NSCLC
Tislelizumab with chemotherapy before surgery improves survival in Chinese lung cancer patients
In a phase III RCT of 453 Chinese adults with resectable stage II-IIIA NSCLC, perioperative tislelizumab plus neoadjuvant chemotherapy signi…
Adding tislelizumab to chemotherapy before surgery helped Chinese lung cancer patients live longer, with a 79.3% three-year survival rate ve…
Phase 3 trial of pembrolizumab versus placebo after surgery for Stage IB-IIIA NSCLC posts results
Can a drug help keep lung cancer from returning after surgery?
A Phase 3 randomized controlled trial in 1177 participants with resected Stage IB-IIIA NSCLC compared adjuvant pembrolizumab to placebo.
A large trial tested whether the drug pembrolizumab helps keep early-stage lung cancer from returning after surgery for over 1,100 patients.
Phase 2 trial finds no significant PFS benefit adding SABR to nivolumab in advanced NSCLC
Does adding targeted radiation to immunotherapy help advanced lung cancer?
A phase 2 randomized trial in 50 adults with metastatic NSCLC found no significant difference in 6-month progression-free survival (49% vs 4…
Adding high-dose radiation to immunotherapy did not improve outcomes or reduce side effects for advanced lung cancer patients who had alread…
Global disparities persist in access to molecular diagnostics and novel therapies for advanced NSCLC
Why does where you live still determine your lung cancer care?
A narrative review synthesizing evidence from guidelines and real-world studies describes persistent global disparities in access to molecul…
Where you live still decides if you get advanced lung cancer tests and treatments, creating a harsh reality where geography and income deter…
Questions about Non-Small Cell Lung Cancer
Can morning timing of immune checkpoint infusions improve survival outcomes in metastatic non-small cell lung cancer patients?
Morning timing of immune checkpoint infusions is linked to better survival in metastatic non-small cell lung cancer, while other new drugs like magrolimab have not shown clear benefits.
Full answer →Does a phase III trial show sublobar resection is better than lobectomy for small peripheral non–small cell lung cancer?
Yes, a phase III trial (CALGB 140503) found sublobar resection noninferior to lobectomy for disease-free survival in small peripheral NSCLC ≤2 cm.
Full answer →How do bispecific antibodies and CAR T-cell therapy work for advanced non–small cell lung cancer?
Bispecific antibodies and CAR T-cell therapy are two immunotherapies being tested for advanced NSCLC; bispecific antibodies show more clinical progress, while CAR T faces challenges like toxicity and tumor trafficking.
Full answer →What does the research say about using chemotherapy versus immunotherapy for advanced Non-Small Cell Lung Cancer?
For advanced NSCLC, immunotherapy (especially pembrolizumab) is highly effective for high PD-L1 tumors, while chemotherapy remains a backbone; combining both may improve outcomes.
Full answer →How does high PD-L1 expression affect treatment choices for advanced Non-Small Cell Lung Cancer?
High PD-L1 expression (≥50%) often makes immunotherapy, such as pembrolizumab, a first-line option for advanced NSCLC, but other factors like mutations also guide treatment.
Full answer →Can you explain the global disparities in access to new therapies for advanced Non-Small Cell Lung Cancer?
Global disparities in access to new NSCLC therapies stem from differences in drug approval, cost, testing infrastructure, and healthcare system resources.
Full answer →Is camrelizumab associated with a higher risk of disease progression compared to pembrolizumab?
In nonsquamous advanced NSCLC, camrelizumab was linked to a higher risk of disease progression and death than pembrolizumab in second-line or later treatment, based on one real-world study.
Full answer →Does real-world data support using pembrolizumab for my advanced Non-Small Cell Lung Cancer?
Yes, real-world data from over 17,500 patients shows pembrolizumab is effective as first-line treatment for advanced NSCLC with high PD-L1 (≥50%), with median overall survival of 21 months and 29% survival at 5 years.
Full answer →